Connaughton Bernadette's Form 4 filing
Halozyme Therapeutics, Inc. (HALO) · filed Oct 1, 2025
- Accession no.
- 0001662521-25-000005
- Filed
- Oct 1, 2025
- Trade date
- Oct 1, 2025
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $150.5K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Connaughton BernadetteCIK 0001662521 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents a weighted average sales price per share. The shares were sold at prices ranging from $74.64 to $75.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Referenced by the price of 1 transaction in Table I.
- F3
Represents a weighted average sales price per share. The shares were sold at prices ranging from $75.64 to $75.92. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Referenced by the price of 1 transaction in Table I.